09:53 AM EST - QLT Inc. : announced positive final results from its international, multi-centre, Phase 1b clinical trial of repeated treatments of oral QLT091001 in subjects with Leber Congenital Amaurosis or Retinitis Pigmentosa due to inherited genetic mutations in retinal pigment epithelium or lecithin:retinol acyltransferase. QLT Inc.
shares T.QLT are trading down $0.11 at $7.14.
